Y-mAbs Therapeutics Inc investor relations material

Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Our clinical programs are focused on DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.